On the public citation graph

Development and Validation of a New Risk Assessment Model for Immunomodulatory Drug-Associated Venous Thrombosis Among Chinese Patients with Multiple Myeloma

https://doi.org/10.2139/ssrn.4200370

0 signed · 31 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinte.166.4.458openalex-extracted

Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers

inferredcites →https://doi.org/10.1001/jamaoncol.2016.3350openalex-extracted

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies

inferredcites →https://doi.org/10.1002/(sici)1096-8652(200002)63:2<74::aid-ajh3>3.0.co;2-vopenalex-extracted

Causes of venous thrombosis in fifty Chinese patients

inferredcites →https://doi.org/10.1002/ajh.23504openalex-extracted

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide‐based regimens

inferredcites →https://doi.org/10.1002/ajh.25603openalex-extracted

Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score

inferredcites →https://doi.org/10.1007/s00277-009-0807-6openalex-extracted

Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide

inferredcites →https://doi.org/10.1007/s11239-015-1311-6openalex-extracted

The epidemiology of venous thromboembolism

inferredcites →https://doi.org/10.1016/j.thromres.2012.11.014openalex-extracted

A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin

inferredcites →https://doi.org/10.1016/j.thromres.2015.07.004openalex-extracted

Family history of venous thromboembolism and risk of hospitalized thromboembolism in cancer patients: A nationwide family study

inferredcites →https://doi.org/10.1016/s0049-3848(00)00265-6openalex-extracted

Protein C and Protein S Deficiencies Are the Most Important Risk Factors Associated with Thrombosis in Chinese Venous Thrombophilic Patients in Taiwan

inferredcites →https://doi.org/10.1016/s0049-3848(09)70136-7openalex-extracted

Effects of race and ethnicity on the incidence of venous thromboembolism

inferredcites →https://doi.org/10.1016/s1470-2045(09)70284-0openalex-extracted

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

inferredcites →https://doi.org/10.1038/sj.leu.2405062openalex-extracted

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

inferredcites →https://doi.org/10.1055/s-0034-1370793openalex-extracted

Venous Thromboembolism in Multiple Myeloma

inferredcites →https://doi.org/10.1056/nejmoa070594openalex-extracted

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

inferredcites →https://doi.org/10.1080/17474086.2016.1194750openalex-extracted

A review of the venous thrombotic issues associated with multiple myeloma

inferredcites →https://doi.org/10.1080/17474086.2020.1751608openalex-extracted

Risk assessment of venous thromboembolism in hematological cancer patients: a review

inferredcites →https://doi.org/10.1093/annonc/mdr392openalex-extracted

Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines

inferredcites →https://doi.org/10.1111/j.1365-2141.2005.05529.xopenalex-extracted

Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study

inferredcites →https://doi.org/10.1111/j.1538-7836.2007.02374.xopenalex-extracted

Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

inferredcites →https://doi.org/10.1111/j.1538-7836.2011.04215.xopenalex-extracted

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysis

inferredcites →https://doi.org/10.1182/asheducation-2010.1.437openalex-extracted

Thrombosis in Multiple Myeloma

inferredcites →https://doi.org/10.1182/blood.2020005125openalex-extracted

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

inferredcites →https://doi.org/10.1182/blood.v98.5.1614openalex-extracted

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy

inferredcites →https://doi.org/10.1186/s12957-015-0592-8openalex-extracted

Venous thromboembolism in cancer patients: an underestimated major health problem

inferredcites →https://doi.org/10.1200/jco.2005.03.0221openalex-extracted

Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group

inferredcites →https://doi.org/10.1200/jco.2007.14.1283openalex-extracted

American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

inferredcites →https://doi.org/10.1200/jco.2009.22.3875openalex-extracted

Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents

inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.8051openalex-extracted

Association of venous thromboembolism with increased mortality in patients with multiple myeloma.

inferredcites →https://doi.org/10.3324/haematol.2012.064444openalex-extracted

Thrombosis is associated with inferior survival in multiple myeloma

inferredcites →https://doi.org/10.6004/jnccn.2018.7273openalex-extracted

Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.